Senate Race Heats Up Over Fentanyl Investments

LANGHORNE, Pa. — As Pennsylvania's Senate race approaches a staggering $360 million in ad spending, candidates' personal financial portfolios have taken center stage. Reports reveal that incumbent Sen. Bob Casey (D-Pa.) holds a minor stake in Yichang Humanwell, a Chinese company that produces legal fentanyl for domestic use in China. Additionally, Casey is linked to two other Chinese fentanyl manufacturers, Jiangsu Nhwa Pharmaceutical and Sinopharm Group, raising questions about his investments amid a national fentanyl crisis. His Republican opponent, Dave McCormick, has capitalized on this issue, emphasizing the devastating impact of fentanyl in America, which he claims has resulted in deaths equivalent to “two Vietnams” last year. However, McCormick has faced scrutiny for his own past investments in Chinese companies, including a $1.7 million stake in Yichang Humanwell while he was CEO of Bridgewater Associates. McCormick attempted to differentiate his previous business dealings from Casey's personal investments, labeling Casey a "liar and hypocrite" for owning similar stocks. In response, Casey's campaign accused McCormick of profiting from Chinese fentanyl investments, asserting that he directly invested millions in the industry. McCormick, however, has released ads attacking Casey for his perceived weakness on border policy, claiming that Casey's investments contradict his criticisms of McCormick. The escalating exchange highlights the candidates' contrasting narratives as they vie for voter support in a race increasingly defined by the fentanyl crisis and personal accountability.